Anticancer effects of α-Bisabolol in human non-small cell lung carcinoma cells are mediated via apoptosis induction, cell cycle arrest, inhibition of cell migration and invasion and upregulation of P13K/AKT signalling pathway.

Abstract

This molecule showed promising anticancer features and could be developed as a potent lead candidate for the management and treatment of NSCLC.